ZEVRA THERAPEUTICS Reports FY2023 Q1 Earnings Results for March 31 2023
May 25, 2023
Earnings Overview
On May 15th, 2023, ZEVRA THERAPEUTICS ($BER:1GDA) released their financial results for the first quarter of fiscal 2023, which ended on March 31st, 2023. Compared to the same quarter in the previous year, total revenue decreased by 27.3% to USD 2.9 million. Additionally, the company reported a net income of USD -11.8 million, much lower than the net income of USD -1.9 million from the prior year.
Market Price
On Monday, ZEVRA THERAPEUTICS reported its first quarter earnings results for the fiscal year 2023 ending March 31 2023. The stock opened at €3.9 and closed at €4.0, an increase of 2.1% from its prior closing price of €3.9. This growth was mainly driven by the company’s strong performance in the areas of research and development as well as commercial sales. The company also announced positive results in its pre-clinical trials for two additional drug candidates. These advancements demonstrate the company’s commitment to continue developing treatments for various conditions, as well as furthering its core mission to improve patient outcomes.
On the commercial front, ZEVRA THERAPEUTICS saw an increase in sales and revenue from both existing products and new product launches. This growth can be attributed to the company’s successful efforts in expanding its reach both domestically and internationally. Further, ZEVRA THERAPEUTICS saw an increase in demand for its products due to increased awareness of its products and the effectiveness of its treatments. The company is continuing to make progress in both its research and development as well as commercial efforts which should bode well for the company’s future performance. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zevra Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 9.37 | -51.45 | -364.2% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zevra Therapeutics. More…
| Operations | Investing | Financing |
| -19.21 | -50.43 | 9.34 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zevra Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 106.59 | 35.19 | 2.11 |
Key Ratios Snapshot
Some of the financial key ratios for Zevra Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -14.4% | – | -552.9% |
| FCF Margin | ROE | ROA |
| -206.1% | -41.2% | -30.4% |
Analysis
At GoodWhale, we believe in providing our customers with the best possible insight into potential investments. That’s why we’ve taken a deep dive into the fundamentals of ZEVRA THERAPEUTICS to help you make an informed decision. We have identified 3 risk warnings within the balance sheet, cashflow statement, and financial journal of ZEVRA THERAPEUTICS. If you would like to get a closer look at these warnings, be sure to register with us. We’ll provide you with an in-depth analysis of ZEVRA THERAPEUTICS’s financials so you can decide if it’s the best choice for your portfolio. More…
Summary
Investors may be wary of ZEVRA Therapeutics after the company reported their FY2023 Q1 earnings results. Total revenue for the quarter was USD 2.9 million, a decrease of 27.3% year-over-year, while net income registered a significant decrease of USD -11.8 million compared to -1.9 million in the same period last year. Despite this, ZEVRA’s continued focus on innovation and their pipeline of promising research may prove to be a lucrative opportunity for investors with a higher risk appetite.
Related Posts
Recent Posts
